Literature DB >> 7932575

Antiproliferative properties of polyamine analogues: a structure-activity study.

R J Bergeron1, J S McManis, C Z Liu, Y Feng, W R Weimar, G R Luchetta, Q Wu, J Ortiz-Ocasio, J R Vinson, D Kramer.   

Abstract

A basis set of polyamine analogues was designed and synthesized. These compounds were used to initiate a systematic investigation of the role of chain length, terminal nitrogen alkyl group size, and symmetry of the methylene backbone in the antineoplastic properties of polyamine analogues. New synthetic methods predicated on our earlier polyamine fragment synthesis are described for accessing the tetraamines of interest. An unsymmetrically substituted diamine reagent, N-(tert-butoxycarbonyl)-N,N'-bis(mesitylenesulfonyl)-1,4-diaminobu tane, was developed for entry into unsymmetrical tetraamines. All of the tetraamines synthesized were first evaluated in a murine leukemia L1210 cell IC50 assay at 48 and 96 h. In an attempt to correlate this behavior with some aspect of polyamine metabolism, each compound was tested for its ability to compete with spermidine for the polyamine uptake apparatus, its impact on the polyamine biosynthetic enzymes ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (AdoMetDC), and its effect on the polyamine-catabolizing enzyme spermidine/spermine N1-acetyltransferase (SSAT) and on polyamine pools. While there was no obvious correlation between the 48 and 96 h IC50's and the impact of the analogues on polyamine metabolism, there were other structure-activity relationships. Correlations were observed to exist between chain length and IC50's and between terminal alkyl substituents and impact on Ki, ODC, and AdoMetDC. Also, preliminary studies suggest a relationship may exist between the 48 and 96 h IC50 activities and the analogue's chronic toxicity in vivo. Finally, when the overall length of the polyamine backbone was held constant, the symmetry of the methylene chains of the polyamine fragments was shown to be unimportant to the compound's activity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7932575     DOI: 10.1021/jm00047a004

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  17 in total

1.  Design, Synthesis, and Testing of Polyamine Vectored Iron Chelators.

Authors:  Raymond J Bergeron; Shailendra Singh; Neelam Bharti; Yi Jiang
Journal:  Synthesis (Stuttg)       Date:  2010       Impact factor: 3.157

Review 2.  Recent advances in the development of polyamine analogues as antitumor agents.

Authors:  Robert A Casero; Patrick M Woster
Journal:  J Med Chem       Date:  2009-08-13       Impact factor: 7.446

Review 3.  Current status of the polyamine research field.

Authors:  Anthony E Pegg; Robert A Casero
Journal:  Methods Mol Biol       Date:  2011

4.  Bisethylnorspermine lipopolyamine as potential delivery vector for combination drug/gene anticancer therapies.

Authors:  Yanmei Dong; Jing Li; Chao Wu; David Oupický
Journal:  Pharm Res       Date:  2010-06-25       Impact factor: 4.200

5.  Phase 1 study of N1-N11-diethylnorspermine (DENSPM) administered TID for 6 days in patients with advanced malignancies.

Authors:  R R Streiff; J F Bender
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

Review 6.  Recent advances in delivery of drug-nucleic acid combinations for cancer treatment.

Authors:  Jing Li; Yan Wang; Yu Zhu; David Oupický
Journal:  J Control Release       Date:  2013-04-25       Impact factor: 9.776

7.  Lipophilic lysine-spermine conjugates are potent polyamine transport inhibitors for use in combination with a polyamine biosynthesis inhibitor.

Authors:  Mark R Burns; Gerard F Graminski; Reitha S Weeks; Yan Chen; Thomas G O'Brien
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

8.  A novel polyamine analog inhibits growth and induces apoptosis in human breast cancer cells.

Authors:  Yi Huang; Erin R Hager; Dawn L Phillips; Valerie R Dunn; Amy Hacker; Benjamin Frydman; John A Kink; Aldonia L Valasinas; Venodhar K Reddy; Laurence J Marton; Robert A Casero; Nancy E Davidson
Journal:  Clin Cancer Res       Date:  2003-07       Impact factor: 12.531

9.  Phase I trial of the polyamine analog N1,N14-diethylhomospermine (DEHSPM) in patients with advanced solid tumors.

Authors:  George Wilding; David King; Kendra Tutsch; Marcia Pomplun; Chris Feierabend; Dona Alberti; Rhoda Arzoomanian
Journal:  Invest New Drugs       Date:  2004-04       Impact factor: 3.850

10.  Polyamine analogues bind human serum albumin.

Authors:  R Beauchemin; C N N'soukpoé-Kossi; T J Thomas; T Thomas; R Carpentier; H A Tajmir-Riahi
Journal:  Biomacromolecules       Date:  2007-09-22       Impact factor: 6.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.